R enal fibrosis is a common pathway of tissue remodeling involved in most chronic kidney diseases, 1 regardless of their etiology. We have previously shown that fibrosis plays a pivotal role in ischemic renal injury induced by renal artery stenosis (RAS) in mice and pigs. 2, 3 The ability to determine the degrees of renal fibrosis may be beneficial for monitoring disease progression and management. Currently, kidney biopsy is the reference standard for fibrosis evaluation, but being an invasive procedure, its application is limited. Thus, developing noninvasive imaging modalities for kidney fibrosis evaluation is greatly needed.
Among the imaging techniques currently being utilized for evaluating in renal fibrosis, magnetic resonance imaging (MRI) 4 with or without gadolinium enhancement shows considerable potential. Yet, computed tomography (CT) provides better temporal and spatial resolution, as well as quantitative power for contrast agents with high atomic numbers. However, identification of renal fibrosis with noncontrast CT remains challenging. Furthermore, gadolinium or iodine administration for magnetic resonance and CT contrast may not be feasible for all subjects and may introduce a risk of contrast-induced nephropathy. 5 Notably, CT offers prominent advantages in terms of speed of image acquisition, relative availability, spatial resolution, and tissue penetration.
Conventional CT contrast agent formulations have charged relatively little over the last 60 years. Thus, there is a need to develop new metal-based agents for x-ray imaging. Gold nanoparticles (AuNPs) have been an attractive candidate because of their superior x-ray attenuation properties. 6 Polyethylene glycol (PEG) coating prevents bare AuNP aggregation and makes them stable as a contrast agent for CT imaging. 7 Gold nanoparticles are safe, small, and readily excreted by the kidneys, with little retention in the liver and spleen. Antibody-conjugated AuNPs have been used by electron microscopy and as a targeted contrast agent for detecting tumors by CT imaging. 8 Collagen-I is one of the major components of pathological fibrosis, 9 and selectively directing AuNP at collagen-I may be useful for the identification of injured kidneys. In this study, we describe the production and evaluation of AuNPs conjugated with an anti-collagen-I antibody (Co-I-AuNPs) and hypothesized that these can be used as CT imaging contrast to detect renal fibrosis.
METHODS
All animal protocols were approved by the Mayo Clinic Institute Animal Care and Use Committee. A total of 44 mice were used for this study. Renal artery stenosis was induced in mice by surgical placement of a 0.15-mm-diameter arterial cuff, whereas sham surgeries without placement of a cuff were performed in the control group, as we previously described. 10 Gold nanoparticles were coated with PEG and conjugated with anti-collagen-I antibody, and their size was determined with an electron microscope and nanoparticle tracking analysis (NTA). The success of antibody conjugation was tested in vitro using a collagencoated plate and sections of stenotic mouse kidneys (2 weeks after RAS). Subsequently, Co-I-AuNPs were intra-arterially injected in mice with unilateral RAS. Four hours later, the mice were scanned with multidetector CT (MDCT) to evaluate renal fibrosis in vivo and then ex vivo using micro-CT and trichrome staining.
AuNP Synthesis, Characterization, and Antibody Conjugation
Gold nanoparticles were prepared following previously published methods, 11, 12 with slight modifications. To prepare 50 mg AuNPs in solution, 250 mL of nanopure water was boiled in a 500-mL flask with high-speed stirring. Then, 1 mL of 5% gold chloride solution (99.99% purity), which contains 50 mg gold metal (Salt Lake Metals, UT), was added and boiled for 3 more minutes, then 2.5 mL 5% sodium citrate dihydrate (Sigma) was added, boiled for 30 minutes, and allowed to cool at room temperature. PEGylation of AuNPs was then performed to prevent aggregation and provide sites for antibody conjugation. For PEGylation, Poly(ethylene glycol) (PEG) methyl ether thiol and Thiol-PEG-Carboxyl (Creative PEGWorks, Chapel Hill, NC) were added to reach 100:1 and 50:1 molecular ratio to gold and incubated for 1 hour with slow stirring at room temperature. The PEG-coated AuNP solution was transferred to 50 mL Falcon tubes and centrifuged at 10,000g for 1 hour. Supernatants were carefully removed, and the AuNP pallets were resuspended in 20 mL nanopure water and centrifuged at 10,000g for 1 hour. After 3 centrifugation-resuspension cycles, phosphate-buffered saline (PBS) was added into AuNP pallets to reach a final volume of 2.5 mL. The final gold concentration was 20 mg/mL, based on 50 mg gold initially added for processing.
Gold nanoparticles were characterized using ultraviolet-visible (UV-vis) spectroscopy (Nanodrop 2000c, Thermo Scientific) for the specific peak absorbance at 525 nm wavelength, and their optical density was recorded. To determine their size, 200 μL (20 mg/mL) AuNPs was subjected to transmission electron microscopy analysis (JEOL 1400 TEM, Peabody, MA). Furthermore, the size distribution of AuNPs after coating was assessed by NTA (NanoSight NS300, NanoSight, Amesbury, UK). The AuNP samples were diluted with PBS at a range of concentrations between 4 Â 10 8 and 8 Â 10 8 particles per milliliter in a total volume of 1 mL. Each sample was continuously run through a flow-cell top-plate set up to 20.0°C using a syringe pump (25 μL/min). At least 3 videos of 120 seconds documenting Brownian motion of nanoparticles were recorded and at least 1000 completed tracks were analyzed by the NanoSight software (NTA 2.3.5).
To conjugate anti-collagen-I antibody to PEG-AuNPs, 1 mL of PEG-AuNPs (20 mg/mL) was mixed with 1 mL of freshly made 1-ethyl-3-(3-(dimethylaminopropyl)-carbodiimide (12.5 mg EDC, Life Technologies)/N-hydroxysulfosuccinimide (24 mg NHS, Sigma-Aldrich) EDC/NHS mix and incubated for 30 minutes at room temperature. Then, 10 mL of PBS with 0.05% Tween-20 (PBST) was added and vortexed thoroughly and spun down by centrifugation (6500g for 30 minutes). Most of the supernatant was removed, and 1 mL of collagen-I antibody (Abcam, rabbit polyclonal, 1 mg/mL in PBS) was added. The solution was then sonicated in a water bath sonicator for 10 seconds and incubated for 4 hours at room temperature with mixing; 10 mL of PBST was added and vortexed and spun down by centrifugation at (3500g for 30 min). The supernatant was removed, 1 mL PBS with 1% bovine serum albumin was added to keep its original concentration (20 mg/mL), and the solution was stored at 4°C ready to use. Furthermore, fluorescence labeled (APC)-Co-I-AuNPs were also made for an organ distribution study using the same protocol, except that collagen-I antibody was preconjugated with APC using an APC conjugation kit (Abcam ab201807), following the provided protocol.
Collagen Binding Tests of Co-I-AuNPs
The rationale for tests is summarized in Figure 1D . We used an antirabbit secondary antibody to visualize Co-I-AuNPs bound to collagen in a plate or the kidney tissue, whereas mouse collagen-I and antimouse secondary antibody served as positive control in kidney tissue. A 24-well plate was coated with soluble collagen (50 μg/mL) and blocked with 1% bovine serum albumin, then incubated with collagen-I antibody (3.5 μL per well), Co-I-AuNPs (100 μL/well), or unconjugated AuNPs (100 μL/well) for 1 hour. After washing with PBS 3 times using a plate washer (Elx 50 Auto strip washer, Bio-TEK Instruments), it was incubated with fluorescein isothiocyanate secondary antibody (1:5000) for 1 hour and washed 3 times with PBS. The plate was then detected in a plate reader at 490 nm wavelength. To evaluate the capability of Co-I-AuNPs in detecting RAS-induced kidney fibrosis, frozen sections of both the stenotic and contralateral kidneys were incubated with Co-IAuNPs or a mouse anti-collagen-I antibody (1:100, Abcam) overnight, washed with PBS, and then incubated with antirabbit or antimouse secondary antibody for 1 hour at room temperature. Images were taken with a Zeiss fluorescence microscope (Â20).
AuNP Organ Distribution and Short-Term Safety
To investigate the in vivo distribution of Co-I-AuNPs, APCCo-I-AuNPs (200 μL, 200 mg/kg) were injected through the left carotid artery in mice with unilateral RAS. After 2, 4, or 24 hours (n = 5 each), both the stenotic and contralateral kidneys, spleen, liver, heart, and lung were collected; homogenized in 300 μL PBS; and transferred to a 96-well plate to measure APC signals with a fluorescence plate reader. Two hundred microliters of APC-Co-I-AuNPs was included in the plate and served as injected APC signals. Organ distributions were calculated from organ fluorescence intensity divided by the total fluorescence intensity injected. The kidneys were also homogenized for a hydroxyproline assay to quantify collagen products, and the correlation between kidney APC fluorescence and collagen levels was calculated. Blood samples were collected from the left ventricle 24 hours after AuNP injection (n = 3) and control mice (n = 3) for hematology studies on the Abaxis VetScan HM5 Analyzer and for chemistry on the Piccolo Xpress Chemistry analyzer.
Detection of AuNP In Vivo
For a proof of concept, to test the capability of Co-I-AuNPs in detecting fibrosis in vivo, mice with RAS were injected with 200 mg/kg Co-I-AuNPs or unconjugated AuNP (n = 3 each) and 2 hours later were placed at the center of an annular solid water phantom (Siemens Healthcare, Germany) 20 cm in diameter. They were then scanned by the A-subsystem of a dual-source scanner (SOMATOM CounT, Siemens Healthcare) with a spiral head protocol with 0.35 pitch, 140 kV, 550 mAs, 128 Â 0.6 mm collimation, and 124.5 mGy CTDIvol. All images were reconstructed using the weighted filtered back-projection algorithm, with a medium smooth kernel (D30), the smallest available field-of-view (50 mm Â 50 mm), and the thinnest available slice thickness (0.6 mm). 13 All images were processed on a CT workstation (Syngo. via, Siemens Healthcare).
Micro-CT Imaging
Given the high resolution of micro-CT, spatial distributions of AuNPs within single kidneys were studied in mice with RAS. Mice were injected with 200 mg/kg Co-I-AuNPs or unconjugated AuNPs (n = 3 each). After 2, 4, and 24 hours injection, kidneys were harvested and processed for micro-CT scan, as previously described. 3 After scanning, renal fibrosis was histologically evaluated by trichrome staining. Micro-CT and histological images from the same kidney were coregistered using anatomic landmarks and compared side by side for AuNP signals and tissue fibrosis.
Statistics
Results were expressed as mean ± SEM. Statistical analysis was performed using JMP version 13.0 (SAS Institute, Cary, NC). Comparison between 2 groups was performed using Student t test.
RESULTS
Gold chloride/sodium citrate ratio in our study created bare AuNPs 18.7 ± 0.6 nm in size, which were detected in electron microscope images (Fig. 1A) , whereas NTA showed PEG-coated AuNPs to be 45.3 ± 0.1 nm (Fig. 1B) and Co-I-AuNPs to 62.5 ± 6.8 nm in size. The UV-vis spectroscopy showed that both bare and PEG-coated AuNPs had peak gold absorbance at 525 nm (Fig. 1C) , the typical wavelength for gold. 12 Fluorescence plate reader data showed that Co-I-AuNPs produced a signal comparable with that of a similar concentration of collagen-I antibody on a collagen-coated plate, indicating successful collagen-I conjugation to the AuNP surface (Fig. 1E) .
We then tested whether Co-I-AuNPs can be used to detect renal fibrosis in excised kidneys. Immunohistological staining showed that rabbit Co-I-AuNPs in the stenotic kidney (red) costained with a mouse anti-collagen-I antibody (green) (Fig. 2) , suggesting detection of renal fibrosis. In contrast, unconjugated AuNPs in the stenotic kidney or Co-I-AuNPs in the contralateral kidney did not produce a red signal.
The APC signals were higher in the liver, spleen, and stenotic kidneys than in other organs 2, 4, and 24 hours after APC-collagen-I-AuNPs injection (Fig. 3A) . Furthermore, AuNP fluorescence (stenotic/contralateral ratio) modestly but significantly correlated with the amount of renal collagen quantified by hydroxyproline levels in the stenotic kidneys (Fig. 3B) .
In vivo, MDCT images acquired 2 hours after Co-I-AuNP injection showed the stenotic kidney to be smaller and brighter than the contralateral kidney (59.3 ± 5.1 vs 45.1 ± 1.7 HU; P = 0.05) (Fig. 3C) , whereas the stenotic kidney receiving unconjugated AuNPs had similar intensity compared with the contralateral kidney (48.4 ± 5.9 vs 45.9 ± 5.8 HU) (Fig. 3D) . Ex vivo, micro-CT detected gold signals in stenotic kidneys of Co-I-AuNP-injected mice (white) at locations similar to collagen-positive stained (trichrome) regions in histological sections processed from the same kidney (Fig. 4, A-C) . Furthermore, electron microscopy images confirmed AuNP retention within the stenotic kidney (Fig. 4, D and E) .
There were no significant changes in mouse hematology (red blood cells, hemoglobin, hematocrit, white blood cells, and platelets), electrolyte levels (Na , liver function (alanine transaminase, aspartate aminotransferase, bilirubin, and albumin), and renal function (blood urea nitrogen and creatinine) after AuNP injection in mice after 24 hours (Table 1) , indicating relative short-term safety of AuNPs at the current dose. Interestingly, alkaline phosphatase levels were lower in mice injected with AuNPs, but remained within the normal range for rodents (http://cal.vet.upenn.edu/projects/ssclinic/ refdesk/rodentrr.htm).
DISCUSSION
This study showed that the collagen-I-AuNPs that were produced specifically bind to collagen-I in both a collagen-coated plate in vitro as well as fibrotic murine kidneys ex vivo. Furthermore, the stenotic kidney showed increased Co I-AuNP retention, which correlated with its collagen levels, and micro-CT images demonstrated gold signals in situ in the collagen-I-AuNP-injected kidney colocalizing with subsequently trichrome-stained kidneys. Thus, we developed collagen-I-AuNPs that are able to visualize kidney fibrosis in vitro and in vivo.
The major components of fibrotic tissue belong to the collagen family of extracellular matrix proteins. Molecular imaging techniques that target collagen fibers therefore constitute a useful approach for fibrosis evaluation. Current widely used molecular imaging techniques include optical imaging, which uses fluorescence and bioluminescence probes to detect target molecules 14 but does not provide tomographic anatomic images and is limited to small animals. Single-photon emission CT and positron emission tomography can be used for molecular imaging of scar tissue 15 with better dose sensitivity, and hybrid systems can complement the sensitivity of positron emission tomography/ single-photon emission CT with the anatomy and spatial resolution of CT or MRI, but the requirement for radioactive reagents limits their applications. Importantly, surface functionalization of AuNPs for active targeting, like the PEG coating and collagen antibody conjugation in our study, could enable a transformational shift in CT from an anatomic imaging modality to a combined high-resolution anatomic and molecular imaging modality.
Gold exhibits a relatively high X-ray attenuation coefficient and a longer vascular retention time compared with iodine; it absorbs more photons than iodine (Â3 at 100 keV), enabling higher contrast at lower x-ray dose and higher resolution. 16 Furthermore, AuNPs provide greater x-ray attenuation compared with iodine at low (40-60 kVp) and high (100-140 kVp) tube potentials, 17 which are clinically relevant ranges for diagnostic CT. Another significant advantage of AuNPs compared with other nanoparticles is their facile molecular surface functionalization to promote colloidal stability and enable active targeting. 18 PEGylation increases the blood half-life of AuNPs in vivo, 19 which enables longer circulation time in the bloodstream and accumulation at the site of interest. Thiol ligands have been most widely used because of their strong covalent bonding with gold and strong sites for bispecific peptide bonding. 20 These features enable the production of collagen-I antibody conjugated AuNPs for fibrosis imaging using CT.
In general, AuNPs are considered to be inert, 21 but their size may determine their toxicity and applications. Gold NPs under 2 nm in size are more likely to induce toxicity owing to the ability to irreversibly bind to biomolecules, including DNA, 22 whereas AuNPs greater than 3 nm in size are relatively safe. In our acute study, we did not observe any changes in liver and renal function in mice after arterial AuNP injection, suggesting relative safety. Our data show that 20 nm AuNPs exhibit a broad range of biodistribution, resulting in more organs being exposed to AuNPs, especially in the liver and spleen. Long-term toxicity may be dependent on the accumulation of AuNPs in specific organs and need longer evaluation. A previous study 18 demonstrated that 20 and 40 nm AuNPs were stable for more than 48 hours in physiologic media, whereas 80 nm AuNPs aggregated by 24 hours. Considering a 100 to 200 nm diameter of transvascular pores and fenestrations, 23 AuNPs under 100 nm in size may be preferable for molecular CT imaging. The human dose converted from mouse dose used in our study is around 15 mg/kg, 24 which should be viable for human studies, although the cost might be prohibitive.
One of the main limitations of CT compared with other imaging modalities is the relatively high mass concentration of contrast agents necessary for contrast-enhanced imaging at the site of interest, 25 and 26, 27 demonstrated that the mass concentration of nontargeted AuNPs internalized by cells increased with the initial mass concentration or dose of AuNPs, but a saturation point was reached. For cost effectiveness and decreased off-target accumulation, arterial injections of AuNPs are superior but increase the invasiveness of this approach. Furthermore, this approach needs to be tested in larger animal models, human subjects, and in targeting other matrix components. A newer high-resolution mode is now available and is expected to improve the quality of in vivo MDCT imaging. Our studies did not include K-edge imaging with enhanced AuNP contrast. Photon-counting system could be optimized and may be combined in the future with image postprocessing to estimate tissue AuNP concentration 28 and bio-distributions 29 in vivo and to differentiate gold and iodine in the tissues. 30 Nevertheless, our study demonstrates that surface-modified AuNPs could be used as molecular imaging probe in CT imaging, combining high-resolution anatomic and molecular images. Further developments to refine this approach might render it useful for future applications.
